Wang, Zhisong published the artcileStructure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy, Name: 2-Amino-6-chloropyrido[3,2-d]pyrimidin-4(1H)-one, the publication is Journal of Medicinal Chemistry (2021), 64(11), 7507-7532, database is CAplus and MEDLINE.
Design and synthesis of a series of pyrido[3,2-d]pyrimidine-based toll-like receptor 7/8 dual agonists, e.g., I that exhibited potent and near-equivalent agonistic activities toward TLR7 and TLR8. In vitro, compounds significantly induced the secretion of IFN-α, IFN-γ, TNF-α, IL-1β, IL-12p40, and IP-10 in human peripheral blood mononuclear cell assays. In vivo, compounds significantly suppressed tumor growth in CT26 tumor-bearing mice by remodeling the tumor microenvironment. Addnl., compounds markedly improved the antitumor activity of PD-1/PD-L1 blockade. These results demonstrated that TLR7/8 agonists held great potential as single agents or in combination with PD-1/PD-L1 blockade for cancer immunotherapy.
Journal of Medicinal Chemistry published new progress about 897359-74-9. 897359-74-9 belongs to pyrimidines, auxiliary class Other Aromatic Heterocyclic,Chloride,Amine,Amide, name is 2-Amino-6-chloropyrido[3,2-d]pyrimidin-4(1H)-one, and the molecular formula is C14H20BNO3, Name: 2-Amino-6-chloropyrido[3,2-d]pyrimidin-4(1H)-one.
Referemce:
https://pubchem.ncbi.nlm.nih.gov/compound/Pyrimidine,
Pyrimidine – Wikipedia